0001193125-19-159707.txt : 20190529 0001193125-19-159707.hdr.sgml : 20190529 20190529165555 ACCESSION NUMBER: 0001193125-19-159707 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190522 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20190529 DATE AS OF CHANGE: 20190529 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CONTRAFECT Corp CENTRAL INDEX KEY: 0001478069 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36577 FILM NUMBER: 19862754 BUSINESS ADDRESS: STREET 1: 28 WELLS AVENUE STREET 2: 3RD FLOOR CITY: YONKERS STATE: NY ZIP: 10701 BUSINESS PHONE: 914-207-2300 MAIL ADDRESS: STREET 1: 28 WELLS AVENUE STREET 2: 3RD FLOOR CITY: YONKERS STATE: NY ZIP: 10701 8-K 1 d664615d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 22, 2019

 

 

ContraFect Corporation

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36577   39-2072586

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

28 Wells Avenue, 3rd Floor, Yonkers, New York 10701

(Address of principal executive offices) (Zip Code)

(914) 207-2300

Registrant’s telephone number, including area code

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

   

Trading Symbol(s)

   

Name of each exchange

on which registered

Common Stock,

$0.0001 par value per share

    CFRX    Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☒

 

 

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 22, 2019, Isaac Blech, a member of the Board of Directors (“Board”) of ContraFect Corporation (“Company”), resigned. Mr. Blech did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. Mr. Blech also served as Chairman of the Nominating and Corporate Governance Committee (“Nominating Committee”) and a member of the Audit Committee. Sol J. Barer, Ph.D., a member of the Company’s Board, has been appointed to serve as Chairman of the Nominating Committee. Michael J. Otto, Ph.D., also a member of the Company’s Board, has been appointed to serve as a member of the Audit Committee.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CONTRAFECT CORPORATION

Date:  May 29, 2019

  

By: 

  

/s/ Natalie Bogdanos

   

Natalie Bogdanos

   

General Counsel and Corporate Secretary